Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSOUZA, Aline de
dc.contributor.authorSCARIM, Caue Benito
dc.contributor.authorCOTRIM, Paulo Cesar
dc.contributor.authorBARBOSA JUNIOR, Fernando
dc.contributor.authorROCHA, Bruno Alves
dc.contributor.authorCALIXTO, Leandro Augusto
dc.contributor.authorCORREIA, Cristiano Jesus
dc.contributor.authorARAUJO, Gabriel Lima de Barros
dc.contributor.authorLOBENBERG, Raimar
dc.contributor.authorBOU-CHACRA, Nadia Araci
dc.contributor.authorBREITHAUPT-FALOPPA, Ana Cristina
dc.date.accessioned2024-04-05T19:32:04Z
dc.date.available2024-04-05T19:32:04Z
dc.date.issued2024
dc.description.abstractBackground: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 mu g/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/08332-3]
dc.identifier.citationNANOMEDICINE, v.19, n.4, p.293-301, 2024
dc.identifier.doi10.2217/nnm-2023-0263
dc.identifier.eissn1748-6963
dc.identifier.issn1743-5889
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58893
dc.language.isoeng
dc.publisherFUTURE MEDICINE LTDeng
dc.relation.ispartofNanomedicine
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright FUTURE MEDICINE LTDeng
dc.subjectchylomicronseng
dc.subjectcycloheximideeng
dc.subjecthydroxymethylnitrofurazoneeng
dc.subjectlymphatic systemeng
dc.subjectnanostructured lipid carriereng
dc.subject.otherin-vitroeng
dc.subject.otherdrug-deliveryeng
dc.subject.othersystemeng
dc.subject.othertransporteng
dc.subject.wosBiotechnology & Applied Microbiologyeng
dc.subject.wosNanoscience & Nanotechnologyeng
dc.titleHydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in ratseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalSOUZA, Aline de:Univ Sao Paulo, Fac Pharmaceut Sci, BR-05508000 Sao Paulo, SP, Brazil
hcfmusp.author.externalSCARIM, Caue Benito:Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Drugs & Med, BR-14800901 Araraquara, Brazil
hcfmusp.author.externalBARBOSA JUNIOR, Fernando:Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Lab Toxicol & Essential Met, BR-14040903 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalROCHA, Bruno Alves:Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Lab Toxicol & Essential Met, BR-14040903 Ribeirao Preto, SP, Brazil
hcfmusp.author.externalCALIXTO, Leandro Augusto:Univ Fed Sao Paulo, Inst Environm Chem & Pharmaceut Sci, Dept Pharmaceut Sci, BR-09913030 Diadema, SP, Brazil
hcfmusp.author.externalARAUJO, Gabriel Lima de Barros:Univ Sao Paulo, Fac Pharmaceut Sci, BR-05508000 Sao Paulo, SP, Brazil
hcfmusp.author.externalLOBENBERG, Raimar:Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2T9, Canada
hcfmusp.author.externalBOU-CHACRA, Nadia Araci:Univ Sao Paulo, Fac Pharmaceut Sci, BR-05508000 Sao Paulo, SP, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcPAULO CESAR COTRIM
hcfmusp.contributor.author-fmusphcCRISTIANO DE JESUS CORREIA
hcfmusp.contributor.author-fmusphcANA CRISTINA BREITHAUPT FALOPPA
hcfmusp.description.beginpage293
hcfmusp.description.endpage301
hcfmusp.description.issue4
hcfmusp.description.volume19
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1168229438
hcfmusp.origem.pubmed38270378
hcfmusp.origem.scopus2-s2.0-85186626773
hcfmusp.origem.wosWOS:001148395300001
hcfmusp.publisher.cityLONDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceBOREN J, 1994, J BIOL CHEM, V269, P25879eng
hcfmusp.relation.referenceChappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748eng
hcfmusp.relation.referenceChaudhary S, 2015, INT J PHARMACEUT, V485, P108, DOI 10.1016/j.ijpharm.2015.02.070eng
hcfmusp.relation.referenceChaudhary S, 2014, J DRUG TARGET, V22, P871, DOI 10.3109/1061186X.2014.950664eng
hcfmusp.relation.referenceChavda H.V., 2010, Syst. Rev. Pharm, V1, P62eng
hcfmusp.relation.referenceChung MC, 2003, BIOORGAN MED CHEM, V11, P4779, DOI 10.1016/j.bmc.2003.07.004eng
hcfmusp.relation.referenceDahan A, 2005, EUR J PHARM SCI, V24, P381, DOI 10.1016/j.ejps.2004.12.006eng
hcfmusp.relation.referenceDas S, 2017, INT J BIOL MACROMOL, V102, P996, DOI 10.1016/j.ijbiomac.2017.04.098eng
hcfmusp.relation.referencede Souza A, 2023, CHEM AFR, V6, P837, DOI 10.1007/s42250-022-00547-6eng
hcfmusp.relation.referencede Souza A, 2020, COLLOID SURFACE B, V193, DOI 10.1016/j.colsurfb.2020.111097eng
hcfmusp.relation.referenceFan ZY, 2013, INT J PHARMACEUT, V445, P141, DOI 10.1016/j.ijpharm.2013.01.070eng
hcfmusp.relation.referenceFu Q, 2013, INT J PHARMACEUT, V448, P290, DOI 10.1016/j.ijpharm.2013.01.065eng
hcfmusp.relation.referenceHerman T.F., 2023, First Pass Effecteng
hcfmusp.relation.referenceJitta SR., 2022, AAPS PHARMSCITECH, V23, P116eng
hcfmusp.relation.referenceJitta SR, 2024, DRUG DELIV TRANSL RE, V14, P116, DOI 10.1007/s13346-023-01386-9eng
hcfmusp.relation.referenceKar N, 2017, EUR J PHARM SCI, V104, P196, DOI 10.1016/j.ejps.2017.03.046eng
hcfmusp.relation.referenceKhan AA, 2013, INT J NANOMED, V8, P2733, DOI 10.2147/IJN.S41521eng
hcfmusp.relation.referenceKhan S, 2016, EUR J PHARM BIOPHARM, V109, P149, DOI 10.1016/j.ejpb.2016.10.011eng
hcfmusp.relation.referenceMennini N, 2016, INT J PHARMACEUT, V515, P684, DOI 10.1016/j.ijpharm.2016.11.013eng
hcfmusp.relation.referenceMonteiro LM, 2017, INT J ANTIMICROB AG, V50, P88, DOI 10.1016/j.ijantimicag.2017.01.033eng
hcfmusp.relation.referenceMonteiro LM, 2015, BRAZ J PHARM SCI, V51, P561, DOI 10.1590/S1984-82502015000300008eng
hcfmusp.relation.referenceMonteiro LM., 2017, BIO MED RES INT, V2017, P1eng
hcfmusp.relation.referenceMoore JE, 2018, ANNU REV FLUID MECH, V50, P459, DOI 10.1146/annurev-fluid-122316-045259eng
hcfmusp.relation.referenceOrganizacao Panamericana da Saude-Organizacao Mundial da Saude, 2016, LEISHM INF EP AMeng
hcfmusp.relation.referencePatel P, 2021, EUR J PHARM SCI, V159, DOI 10.1016/j.ejps.2021.105715eng
hcfmusp.relation.referenceSerafim EOP, 2013, ANTIMICROB AGENTS CH, V57, P6106, DOI 10.1128/AAC.02522-12eng
hcfmusp.relation.referencePoonia N, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa-2016-0030eng
hcfmusp.relation.referenceSaleem K, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9121749eng
hcfmusp.relation.referenceShete H, 2013, INT J PHARMACEUT, V454, P584, DOI 10.1016/j.ijpharm.2013.03.036eng
hcfmusp.relation.referenceTrevaskis NL, 2015, NAT REV DRUG DISCOV, V14, P781, DOI 10.1038/nrd4608eng
hcfmusp.relation.referenceWHO, 2021, LEISHM INFeng
hcfmusp.relation.referenceXu Q, 2019, PHARM DEV TECHNOL, V24, P1155, DOI 10.1080/10837450.2019.1646757eng
hcfmusp.relation.referenceYousef M, 2021, J PHARM PHARM SCI, V24, P533, DOI 10.18433/jpps32222eng
hcfmusp.relation.referenceZhang ZC, 2021, ACTA PHARM SIN B, V11, P2449, DOI 10.1016/j.apsb.2020.12.022eng
hcfmusp.relation.referenceZhu QG, 2021, ACTA PHARM SIN B, V11, P2416, DOI 10.1016/j.apsb.2021.04.001eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationfa805865-a64c-43ed-9f12-5c10b38cf2fd
relation.isAuthorOfPublicationfd6721b6-3a47-404f-a2ff-5b6770f85c3d
relation.isAuthorOfPublicationc30b994d-83bd-4dd2-9640-3577754e17a0
relation.isAuthorOfPublication.latestForDiscoveryfa805865-a64c-43ed-9f12-5c10b38cf2fd
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP